Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187479 · ClinicalTrials.gov registry record · NA
Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus
A NA study of Type 2 Diabetes and Kidney Disease, sponsored by Well Cell Global.
- Recruiting
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07187479: Recruiting NA study of Type 2 Diabetes and Kidney Disease, sponsored by Well Cell Global.
NCT07187479 is a NA study of Type 2 Diabetes and Kidney Disease that is actively recruiting participants, run by Well Cell Global. The registered enrollment target is 120 participants, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07187479, a NA study of Type 2 Diabetes and Kidney Disease, is actively recruiting participants, sponsored by Well Cell Global.
- RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
Primary Outcome
Assess the eGFR of patients in the PIR group as compared to the SOC group
Conditions Studied
Interventions
- OTHER Physiologic Insulin Resensitization (PIR)
Study Locations (1)
Arizona
- Arizona Kidney Disease and Hypertension Center - Phoenix
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-10-14 |
| Est. Completion | 2026-06 |
| Phase | NA |
What NCT07187479 shows while recruiting
NCT07187479 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 3,923-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (97% lower).
The record links to 3 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Physiologic Insulin Resensitization (PIR) is the first listed.
NCT07187479 reports a single indexed study location in Arizona.
Frequently Asked Questions
What is clinical trial NCT07187479 about?
NCT07187479 is a clinical study titled "Outcomes of Physiologic Insulin Resensitization (PIR) in Patients With Chronic Kidney Disease and Type 2 Diabetes Mellitus". The purpose of this research is to evaluate outcomes of physiologic insulin re-sensitization (PIR) in patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM).
What is the current status of trial NCT07187479?
This trial is currently recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2025-10-14. Estimated completion is 2026-06.
What conditions does trial NCT07187479 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Kidney Disease, Chronic Kidney Disease (Stages 4 and 5).
What interventions are being tested in trial NCT07187479?
The interventions under investigation include: Physiologic Insulin Resensitization (PIR) (OTHER).
Who is sponsoring clinical trial NCT07187479?
This trial is sponsored by Well Cell Global, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07187479 being conducted?
This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07187479's enrollment target sits among peer trials
120 133rd of 327 higher than 193 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI